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Abstract In a recent study published in this journal it was
claimed that the rate of publications from US-based authors
in the human embryonic stem cell (hESC) research field was
slowing or even declining from 2008 to 2010. It was as-
sumed that this is the result of long-term effects of the Bush
administration’s funding policy for hESC research and the
uncertain policy environment of recent years. In the present
study, we analyzed a pool of more than 1,700 original hESC
research papers published world-wide from 2007 to 2011. In
contrast to the previous study, our results do not support the
hypothesis of a decline in the productivity of US-based
research but rather confirm a nearly unchanged leading
position of US research in the hESC field with respect to
both publication numbers and impact of research. Moreover,
we analyzed about 500 papers reporting original research
involving human induced pluripotent stem cells (hiPSCs)
published through 2011 and found a dominant position of
US research in this research field as well.
Keywords Human embryonic stem cells (hESC) . Human
induced pluripotent stem cells (hiPSC) . Publication
numbers . Impact factors . Citation frequencies
Introduction
The question how the effects of the federal US funding
policy for human embryonic stem cell (hESC) research
can be measured is a matter of debate. Whereas some have
valued publication numbers as evidence for a growing
underperformance of the United States in this research field
[1, 2], we observed an unaltered high level of contribution
of the United States to hESC research over the last decade
[3, 4]. In addition, several studies claimed that the Bush
administration’s funding policy was causative for the pref-
erential use of only a few hESC lines, namely Wicell’s H1
and H9 lines [5–7], while we have shown that the preferential
use of certain hESC lines is independent of a nation’s stem cell
policy [4]. Rather, we found that the current global stem cell
usage patterns can be effortlessly explained by a cumulative
advantage process independent of restrictive or permissive
policy influence, and we showed that this model nearly per-
fectly mirrors factual worldwide stem cell usage patterns [8].
In a recent paper published in this journal and entitled
“The Race Is On: Human Embryonic Stem Cell Research
Goes Global”, regional differences in hESC lineage use and
a decrease in studies from US-based research groups were
reported for a period spanning from 2008 to 2010 [9]. Inter
alia it was assumed that lingering effects of the prohibitive
stem cell funding policies between 2001 and 2008 and an
uncertain policy environment of the first half of the Obama
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administration was responsible for an observed decrease in
productivity of US-based groups in this field. It was stated
that more nations joined the hESC “race” in this period of
time by “aggressively” publishing in the peer-reviewed lit-
erature. Apart from the problem that counting papers pub-
lished until 2010 might be not a suitable measure for
possible effects of the altered stem cell funding policy
established in the second half of 2009, we have additional
doubts on the conclusions drawn in this study.
While the differences in the regional usage of hESC lines
observed by DeRouen and co-workers were already reported
before [4], our analysis of a comprehensive dataset on original
hESC literature published from 2007 to 2011 shows a differ-
ent situation for US-based hESC research than reported in the
study by DeRouen and co-workers. Our investigation of
hESC research papers reveals that both the US share in total
numbers of publications produced worldwide and the impact
of papers originating from US-based research groups
remained nearly unaltered over the last years. In addition,
our analysis of human induced pluripotent stem cell (hiPSC)
research published through 2011 indicates a moderate decline
in the US dominance in this politically non-regulated research
field but nevertheless confirms the strong and leading position
of US-based hiPSC research.
Methods
Data Repositories and Publication Selection
The analyses are based on two literature data banks harbour-
ing 2,407 original research studies involving experimental
use of hESCs published from 1998 to 2011 and 514 original
hiPSC research papers published from 2007 to 2011, respec-
tively. The data bank on hESC studies was established in
2005 according to the methods reported earlier [10] and also
contains information on nearly 1,600 hESC lines and their
usage in research based on published data. The hiPSC paper
repository was set up in 2009 according to the principles
reported recently [11]. Both datasets are updated on an
annual basis by manual inspection of large paper pools
resulting from the respective searches of the PubMed data-
base accessible through the NIH National Library of Med-
icine (NIH/NLM). It should be noted, that both repositories
only contain studies that report on original experimental
work on human pluripotent stem cells. Reviews, Comments,
Editorials as well as work on ethical and political aspects of
research in human pluripotent stem cells are not included.
We also did not consider studies, in which only material or
cells derived from hESCs or hiPSCs (such as RNA from
hESCs or cardiomyocytes derived from hiPSCs) were used
or in which data obtained in previous studies (e. g. gene
expression data available from the GEO database) were
analysed. Publications of protocols that summarize previously
reported experimental work were also excluded from our
datasets. Assignment of papers to countries was according to
the institutional affiliation of the corresponding author.
From 2007 to 2011, 1934 studies involving use of hESCs
and 512 hiPSC research papers in line with the outlined
criteria were published, respectively. Papers pre-published
in 2011 but printed only in 2012 were not included in the
analysis. In a portion of these studies both hESCs and
hiPSCs were used resulting in an intersection of 392 papers
which are present in both datasets. In 174 of those papers
hESCs and hiPSCs are either investigated in parallel e. g. to
drive conclusions on a broader panel of human pluripotent
stem cells [4, 12], or hiPSCs were used to confirm results
obtained with hESCs in the same study. However, in the
remaining 218 of these studies hESCs were only used for
mere comparison with hiPSCs e. g. to verify pluripotency of
novel hiPSC lines. These 218 papers were excluded from
the analysis of hESC studies giving rise to a pool of 1,716
hESC research papers published from 2007 to 2011 that
were analysed in the present study. In case of hiPSC re-
search activities, analysis was started in 2008 so that pio-
neering work on hiPSCs [13, 14] was omitted. The complete
paper list is available on request.
Determination of Average Impact Factors
The determination of impact factors was performed using
the Five Year Impact Factors for 2010 published in the
Journal Citation Reports [15]. Of 361 journals that pub-
lished experimental work on hESCs, 33 did not have an
Impact Factor, affecting 45 papers. In case of hiPSC studies,
10 of 123 journals that published experimental work did not
have an Impact Factor affecting 12 studies. These 45 and 12
papers, respectively, were not included in the analyses.
Consequently, 1,671 hESC and 500 hiPSC studies were
analysed for Journal Impact Factors. The Five Year Impact
Factor for each journal that had published experimental
hESC or hiPSC work, respectively, was multiplied by the
number of papers that were published in this journal. The
results were added and divided by the total paper numbers to
obtain the average Five Year Impact Factors.
Determination of Average Citation Frequencies
1,289 hESC papers published from 2007 to 2010 and 267
hiPSC research papers published from 2008 to 2010 were
analysed for their overall citation frequencies by the end of
2011 using the Scopus database (http://www.scopus.com/
home.url). For 4 hESC and 2 hiPSC papers, respectively,
no citation frequency could be determined since the journals
are not listed in the Scopus database. These papers were
omitted from the analysis. Average annual citation
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frequencies were determined by dividing the citation number
by the number of years after the study was published (e. g. for
a study that was published in 2007, number of citations from
2008 to 2011 was summated and divided by 4). Citations in
the year of publication of a paper (in print) were not consid-
ered. Citation analysis was performed in July 2012.
Results
Figure 1 shows the results of our analyses of those 1,716
research papers that involved experimental use of hESCs and
that where published between 2007 and 2011 in English
language journals listed in the Pub Med data base (for details
see suppl. Table 1). Studies in which hESCs were used merely
for comparison with other human pluripotent stem cells such
as hiPSCs were not considered. The number of papers from
US-based and non-US groups markedly increased from 2007
to 2011 (Fig. 1a). We observed a slight slowdown in the
increase of paper numbers from 2009 to 2011, which might
be due to a shift of the scientific interest to hiPSCs in the years
after 2007. However, the share in overall publications in
hESC remained relatively constant between US- and non-
US based groups with a moderate outlier in 2009 (Fig. 1b).
The 714 papers published by US-based groups in this five-
year period account for about 41.6 % of hESC work pub-
lished world-wide. This value is nearly identical to that from
the previous five-year period (2002 to 2006) when the share
of US-based work was 41.2 % (185 of 449 hESC research
papers). Thus, our data do not reveal any decline in the
contribution of US-based research groups to the relative num-
ber of hESC publications. Rather they confirm that the output
of research in hESCs has increased both in and outside the
United States to a nearly indistinguishable degree.
We also investigated in detail the contribution of groups
based in countries with at least 30 research papers in the
hESC field from 2007 to 2011 (suppl. Figure 1). Although
there was a tendency towards an increase in the number of
hESC research studies in most countries from 2007 to 2011,
we did not observe an overall relative increase in the percent
share of studies from these countries in worldwide publica-
tion numbers. For example, whereas the relative share of
studies from Japanese groups remained nearly constant, it
increased markedly for papers from China and rather de-
creased for studies from Israel or Singapore in this period of
time. It should be noted that in some countries with a rather
permissive stem cell policy (such as Israel or Singapore) the
absolute research output remained nearly unchanged over
the past 5 years. On the other hand, we observed an increase
in the number of published studies from Germany which has
one of the most restrictive stem cell policies world-wide. In
general, the number of countries which are home to research
groups publishing results of experimental work involving
hESCs increased from 23 in the period 2002 to 2006 to 35 in
the 2007 to 2011 period.
Although data on publication numbers may provide some
insight in past research activities, they do not give a strong
indication on the actual impact of this work on international
research. We therefore investigated the average Impact Fac-
tor of journals that published hESC work from 2007 to 2011
as a further possible proxy for the potential academic impact
of a nation’s basic and preclinical hESC research. Figure 2a
shows the result of the analysis of those 1,671 hESC re-
search papers that were published from 2007 to 2011 in
journals which have an Impact Factor according to the
Journal Impact Factors list for 2010. The weighted average
Five Year Impact Factor of journals that published hESC
work from 2007 to 2011 was about 7.5. However, hESC
research studies from groups based in certain countries such
as Canada, France and the United States were published in
journals with an higher average Five Year Impact Factor
(9.94, 9.62 and 9.38, respectively) while papers from groups
based in China, Korea or Australia tended to appear in less
influential journals (average Five Year Impact Factor 4.23,
4.80 and 5.57, respectively). In the 5 year period analyzed, a
moderate decrease in the average Impact Factor of Journals
publishing studies from non-US groups was observed, while
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Fig. 1 hESC research papers from 2007 to 2011. Shown are the absolute
number of hESC research papers (a) and the relative share of US
and non-US-based studies in the total number of hESC papers (b)
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with an nearly constant average Impact Factor (Fig. 2b)
underlining the nearly unaltered high visibility of hESC
studies from the United States.
However, the Impact Factor of a journal does not neces-
sarily reflect the actual influence of each individual study
published in this journal. Using the Scopus data base, we
therefore analyzed the factual citation numbers until 2011 of
hESC research papers published from 2007 to the end of
2010. The high impact of journals publishing US-based
hESC research is also reflected in the citation numbers.
hESC research papers published from 2007 to 2010 were
cited at an average frequency of 9.5 per year. However,
studies from the United States were cited at an average of






























































Fig. 2 Impact of Journals that published hESC research papers from
2007 to 2011. a Overall average Five Year Impact Factors 2010 for
hESC research papers published from 2007 to 2011. Data for those 13
countries that contributed more than 30 studies to the hESC research
field in this period are shown individually, data for the remaining 22
nations that contributed to hESC research are merged in “others”. b
Average Five Year Impact Factors 2010 for hESC research papers from















































































































Average citations per study and year
Fig. 3 Average annual citation
frequencies for hESC research
papers published from 2007 to
2010. Citation analysis was
performed for the years 2008 to
2011 starting in the year
following the publication of a
paper. a Average annual citation
frequencies from 2008 to 2011.
b Temporal course of average
citation frequencies for the
years indicated. c Share of
papers within the indicated
range of citations per year in the
total number of studies from the
given countries. Papers were
grouped according to their
average annual citation
frequency from 2008 to 2011
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cited less frequently (Fig. 3a). Of note, there is only a
limited correlation between the average Five Year Impact
Factors of journals that published hESC work and the aver-
age citation frequencies. In addition to papers from US
based groups, only studies from Canada, Germany and the
United Kingdom were cited more frequently than the world-
wide average. Moreover, when average citation frequencies
were investigated on an annual basis, an only moderate
decline was observed for studies published by US groups
from 2007 to 2010. In sharp contrast, average citation fre-
quencies of studies from other countries declined by more
than 50 % from 2007 to 2010 (Fig. 3b). To exclude that the
observed diversity in citation frequencies among papers
from several nations is due to extremely frequent citation
of only a few popular studies we grouped hESC research
papers according to their average citation frequency per year
(Fig. 3c). The share of papers cited less than 10 times per
year was 77.0 % for papers published by non-US groups
from 2007 to 2010, and the proportion of papers cited more
than 30 times per year was only 2.5 %. In case of papers
from groups based in the United States, the share of rarely
cited papers was 64.2 %, and papers with an annual citation
frequency of 30 or more accounted for 8.7 % of all US
studies. Therefore, a rather broad range of hESC papers
contributed to the high citation frequency of US-based
work. Taken together, our data confirm a relatively constant
leadership of US research in the hESC field and strongly
argue against the purported decline in the productivity of US
based groups in the academic arena.
Next, we were interested whether similar or different
trends can be observed in the nearly un-regulated field of
hiPSC research. We analyzed publications on original work
involving hiPSCs that appeared in the past 4 years (2008 to
2011, Fig. 4). By the end of 2011, at least 512 papers
describing experimental work involving hiPSCs were avail-
able for this period from English language journals indexed
in the PubMed data base (for details see suppl. Table 2). A
sharp increase in publication numbers was observed from
2008 to 2011, and both US- and non-US-based groups
markedly contributed to the elevated research output
(Fig. 4a). However, we detected a moderate decrease in
the relative share of studies from US-based groups in world-
wide publication numbers from 66.7 % in 2008 to 48.6 % in
2011 (Fig. 4b). This might be explained by the early publi-
cation of pioneering hiPSC work by several US-based
groups which caused a high popularity of this type of
research in the following years all over the world. It should
be noted that certain countries that significantly contributed
to hESC research in the last decade such as Sweden, Singa-
pore, Israel or Korea did not play a major role in hiPSC
research by the end of 2011.
Finally, we performed an analysis of Journal Impact
Factors and citation frequencies of hiPSC research papers
(Fig. 5). Data for six countries which contributed at least 15
original papers to the hiPSC research field from 2007 to
2011 are shown. Only papers from groups based in Spain
were published in journals with a slightly higher average
impact factor than US studies (Fig. 5a), while papers pub-
lished by groups from the United States from 2008 to 2010
were cited most frequently (Fig. 5b). We observed a good
general correlation between the average Five Year Impact
Factors and the actual citation frequencies. Surprisingly,
studies from Japan which is believed to have a leading
position in the hiPSC research field seem to be less influen-
tial according to both Journal Impact Factors and actual
citation frequency, despite the high number of Japanese
papers in this field. Again, grouping of papers according
to their citation frequency per year revealed, that a major
proportion of studies from the United States were cited more
than 50 times per year. Thus, a rather broad panel of
papers from US groups contributed to the observed high
citation rates. In contrast, only few studies from Japan
























































Fig. 4 hiPSC research papers from 2007 to 2011. Shown are the
absolute number of hiPSC research papers (a) and the relative share
of US and non-US-based studies in the total number of total hiPSC
papers (b)
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a relative decline in output from US-based groups, US
based research continues to occupy a leading position in
the hiPSC field as well.
Discussion
There has been some controversy on the effects of regula-
tory policies on hESC research output and about the reasons
for the preferred usage of an only restricted set of hESC
lines [2–4, 6, 7, 10, 12]. Most recently, it has been suggested
that embargo effects from past restrictive policies in the US
may contribute to a reduced output by US-based researchers
in recent years, while non-US labs thrive because they were
able to freely use any hESC cell line without budget restric-
tions [9]. Our analysis of the available data did not confirm a
reduced relative academic output or impact of US-based
hESC research over time.
In fact, our data show that the number of publications in
the hESC research field increased globally over the past
5 years, independent of a more or less restrictive stem cell
policy or ideology-driven research funding. Although a
short-term effect of a restrictive budget policy might have
delayed research output in the US after 2001 [16], factors
such as general research and alternative budgets, research
capacities and human resources or the availability of re-
search material all contribute to the research output and
may compensate for politically motivated restrictions. For
example, in the United States the state funding for stem cell
research partially exceeded federal funding by the NIH in
the last years [17]. For the US, our data show no decline in
relative contribution to international hESC research as mea-
sured in numbers of published research and in terms of its
impact, and if anything we found a trend towards a relative
increase in the number of citations of work published by
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Fig. 5 Impact of published hiPSC research. a Overall average Five
Year Impact Factors 2010 for hiPSC research papers published from
2008 to 2011. Data for those 6 countries that contributed more than 15
studies to the hiPSC research field in this period are shown individu-
ally, data for the remaining 14 nations that contributed to hiPSC
research are merged in “other”. b Average annual citation frequencies
for hiPSC research papers published from 2008 to 2010. Citation
analysis was performed for the years 2009 to 2011 starting in the year
following the publication of a paper. c Share of hiPSC research papers
within the indicated range of citations per year in the total number of
studies from the given countries. Papers were grouped according to
their average annual citation frequency from 2009 to 2011
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based outside the United States. Independent of the US
situation with 14 hESC research papers published in 2003
(45.2 % of global output), 41 in 2004 (41.8 %), 49 in 2005
(37.1 %) and 174 in 2011 (40.7 %), hESC research output
increased globally with higher numbers of publications,
from 31 in 2003 up to newly 430 in 2011.
The reason for the supposed loss of leadership of the
United States in hESC research or, more generally, pluripo-
tent stem cell research was blamed on the restrictive funding
policy in the US, and its long-term aftereffects. Already in
2006 it was reported that the US share in hESC studies
published through 2004 experienced a decline starting in
2001 [1]. Levine identified the United States as an under-
performer in hESC research relative to the unrelated RNAi
research field [2] although the conclusions of this study
have been challenged [3]. A recent citation analysis identi-
fied a lag in US production in hESC research of up to 40 %
behind anticipated levels when using studies involving
RNAi as a reference [16]. However, this lag was most
prominent from 2001 to 2003 and although RNAi was –
as hESCs – first described in 1998 by a US-based group,
studies involving RNAi might not be the best choice for the
intended comparison. In contrast to pluripotent stem cells,
experimental use of RNAi does neither require a rare and
difficult to propagate material (such as stem cells in complex
culture systems) nor scientists trained in special experimen-
tal skills beyond common molecular biology techniques. In
our hands-on experience [18, 19], both factors limited sig-
nificantly the development of the hESC research field.
There is no doubt that restrictions and regulatory uncertainty
can have a major impact on researchers [20] and may delay or
even prevent scientific progress. However, our analysis of
publications does not confirm but clearly refutes the hypoth-
esis of a relative decline of US productivity in hESC research.
It can only be speculated about the reasons for the appar-
ent discrepancy between our data and the recent findings of
DeRouen and co-workers. While these authors used a data
pool of 2,086 hESC and hiPSC papers published from 1998
to 2010 for their analysis, our dataset for this period of time
contains 1940 original research papers. Thus, the paper pool
seems to be of a comparable size, and inclusion and exclu-
sion criteria may be the prime reason for different results
obtained in both studies. The public availability of the data-
sets used in the paper of DeRouen et al. as well as in other
studies from the same group would have been helpful for
understanding obvious discrepancies. In addition, the period
of time analyzed by DeRouen and co-workers did only span
3 years and might not be sufficient to draw appropriate
conclusions on the principal development of a research
field. Moreover, it may be questionable in general whether
the number of publications alone is a suitable measure for
the impact of a nation’s research. We suggest that taking
additional factors such as Journal Impact Factors and
citation numbers into account may be more adequate. Doing
so, we did not find any evidence for a decline in the US
contribution to the hESC field.
For the essentially unrestricted research on hiPSC we
found a different outcome with respect to the relative weight
of US and global research output. By 2008, neraly 70 % of all
hiPSC work was published by US-based groups, but the US
share in published work on hiPSCs dropped to below 50 % in
2011. At the same time, US-based research in the hiPSC field
maintained a continuing high visibility. It would be premature
to conclude that the observed decline in the relative share of
US contribution to the hiPSC field may reflect a diminished
competitiveness of US research. Rather, we suggest that the
undisputable initial dominance of US research in this field was
due to pioneering work of several US-based groups which
caused a high popularity of hiPSC research in the following
years. A reason for the comparatively fast ascent of hiPSC
research outside of the US might be that a high number of
researchers have been trained by now and are capable to work
with human pluripotent stem cells. The easier availability of
other resources that are needed for this type of research which
were built up during the previous hESC era may also contrib-
ute to the rapid development of the hiPSC field. It is surpris-
ing, however, that research from Japan performed below
average in terms of impact during the reported time frame.
In summary, our data shows an unaltered strong contribu-
tion of US research to the hESC field. This may be supportive
for the hypothesis that research output is obviously not se-
verely hampered by budgetary regulation as long as alterna-
tive budget options are available [16]. Moreover, research on
hiPSCs is characterized by a moderate decrease in US domi-
nance in this field with regard to paper numbers, while the
impact of US research remains at a high level. Factors such as
increasing international collaboration, publication bias or dis-
tribution of resources may have specific effects on this type of
research and require further investigation.
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